OR WAIT null SECS
Felicity Thomas is Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.
March 02, 2020
As compounds become more complex in nature and biological ingredients are more widely used, stability testing approaches must follow suit and provide flexibility for developers.
Assays can provide a useful tool in determining the potential toxicity of drugs throughout the development cycle.
A brief overview of three notable cases of adverse drug reactions.
Despite increasing R&D budgets by bio/pharma companies, returns on this investment are reducing and the cost of bringing an asset to market is increasing.
Metrology has the potential to not only prevent harm to patients but also to support innovative therapeutic options.
Outsourcing stability testing to full-service providers can offer comprehensive benefits to bio/pharma companies.